Speaker's Highlight

• Don Sin University of British Columbia, St. Paul Hospital (Canada)
  Kenneth R. Chapman Toronto General Hospital Research Institute (Canada)
• Parameswaran Nair McMaster University (Canada)
  Carolyn Calfee UCSF (U.S.A.)
• Gregory P. Downey University of Colorado School of Medicine (U.S.A.)
  David A. Schwartz University of Colorado School of Medicine (U.S.A.)
• Neil Schluger Tuberculosis Control Branch, California Department of Public Health (U.S.A.)
  Nick Kim Critical Care & Sleep Medicine, University of California San Diego (U.S.A.)
• Nicola Hananiah Baylor College of Medicine (U.S.A.)
  Jae-Joon Yim Seoul National University College of Medicine (Republic of Korea)
• Koichiro Asano Tokai University School of Medicine (Japan)
  Diahn-Warng Perng Taipei Veterans General Hospital (Taiwan)
• Konstantinos Kostikas University of Ioannina (Greece)
  Karin Klooster University Medical Center Groningen (Kingdom of the Netherlands)

• Anticholinergic therapy in chronic obstructive pulmonary disease

  Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation, breathlessness, cough, and reduced exercise tolerance. Inhaled bronchodilators form the foundation of symptom management because they reduce airway narrowing and help patients breathe more comfortably during daily activity.

  Anticholinergic medicines, also called muscarinic antagonists, are especially important in COPD care. They counter excessive cholinergic bronchomotor tone, promote airway relaxation, and can reduce hyperinflation. Their role ranges from rapid relief during intermittent symptoms to long-term maintenance in patients with frequent breathlessness.

  Treatment decisions should reflect lung function, symptom burden, exacerbation history, inhaler technique, comorbidities, and the patient’s ability to follow a daily regimen. Respiratory medicine programs such as APSR 2022 provide a useful setting for reviewing how these therapies fit within contemporary COPD management.

  The role of muscarinic antagonists

  Acetylcholine released by parasympathetic nerves binds to muscarinic receptors in airway smooth muscle and glands. In COPD, this cholinergic pathway contributes to bronchoconstriction and mucus production. Anticholinergic drugs block muscarinic receptors, particularly the M3 receptor involved in airway contraction.

  Short-acting muscarinic antagonists (SAMAs), such as ipratropium, begin working relatively quickly and may be used for intermittent relief or in acute-care settings. Long-acting muscarinic antagonists (LAMAs), including tiotropium, glycopyrronium, aclidinium, and umeclidinium, provide sustained bronchodilation and are generally preferred for maintenance therapy.

  For many patients, a LAMA improves forced expiratory volume, reduces dynamic hyperinflation, and increases exercise capacity. It may also lower the risk of COPD exacerbations, making this class valuable even when daily symptoms appear modest.

  Matching treatment to COPD patterns

  A patient with occasional symptoms may receive a short-acting bronchodilator for immediate relief, while someone with persistent dyspnea usually benefits from a once- or twice-daily long-acting inhaler. LAMA therapy is often selected as an initial maintenance option when breathlessness, activity limitation, or exacerbation risk is clinically significant.

  When symptoms continue despite a LAMA, adding a long-acting beta2-agonist (LABA) can produce greater bronchodilation than increasing reliance on rescue medication. LABA/LAMA combinations are particularly useful for patients with substantial dyspnea or persistent exercise limitation. The choice should be guided by response, inhaler preference, dosing schedule, and insurance access.

  COPD and asthma can coexist, but their treatment priorities differ. Asthma generally requires anti-inflammatory therapy, while COPD care centers on bronchodilation and risk reduction. Environmental measures also matter; guidance on home trigger control can complement medical care when patients have overlapping airway disease or irritant exposure.

  Comparing commonly used options

  The practical differences between anticholinergic medicines involve duration, device design, dosing frequency, and patient handling. Pharmacologic efficacy is only part of the decision: an inhaler that cannot be used correctly will provide limited benefit regardless of its active ingredient.

  Therapy	Typical role	Dosing pattern	Main practical consideration
  Ipratropium	Short-term relief or acute-care support	Several times daily	Quick action but higher treatment burden
  Tiotropium	Long-term COPD maintenance	Once daily	Extensive clinical experience and sustained effect
  Glycopyrronium	Long-term maintenance	Once or twice daily, depending on device	Useful option across several inhaler formats
  Aclidinium	Long-term maintenance	Usually twice daily	May suit patients who prefer a twice-daily routine
  Umeclidinium	Long-term maintenance	Once daily	Simple schedule with a dry-powder inhaler
  LAMA/LABA combination	Persistent symptoms despite single therapy	Once or twice daily	Greater bronchodilation but requires device-specific training

  The best inhaler is one the patient can operate consistently. Clinicians should check inspiratory flow requirements for dry-powder devices, coordination for metered-dose inhalers, and the ability to load capsules or prepare a dose. Demonstration followed by teach-back is more reliable than asking whether the patient understands.

  Benefits beyond airway opening

  Anticholinergic bronchodilation can reduce air trapping, allowing the lungs to empty more effectively before the next breath. This is important because hyperinflation can make walking, climbing stairs, and speaking feel disproportionately difficult. By improving mechanical efficiency, treatment may support physical activity and pulmonary rehabilitation.

  Maintenance therapy may also reduce exacerbations, especially in patients with a history of flare-ups. Exacerbation prevention requires a broader plan that includes vaccination, smoking cessation, pulmonary rehabilitation, appropriate action plans, and evaluation of inhaler adherence.

  Medication response should be assessed through symptoms and function rather than spirometry alone. Improvements in daily activity, rescue inhaler use, sleep, walking distance, and recovery after exertion can be clinically meaningful even when changes in FEV1 are limited.

  Safety and monitoring

  Anticholinergic inhalers are generally well tolerated because systemic exposure is relatively low. Common effects include dry mouth, throat irritation, cough, and an unpleasant taste. Good hydration, oral care, and review of inhaler technique may reduce discomfort and improve persistence with treatment.

  Rare but important concerns include urinary retention, worsening narrow-angle glaucoma if medication reaches the eyes, palpitations, and hypersensitivity reactions. Patients with prostatic obstruction, glaucoma, significant cardiac disease, or complex medication regimens may need individualized review. Nebulized treatment requires particular attention to mask fit so mist does not enter the eyes.

  A sudden increase in breathlessness should not automatically be managed by taking extra maintenance doses. New or rapidly worsening symptoms may indicate an exacerbation, pneumonia, pulmonary embolism, heart failure, or another urgent condition. A written COPD action plan helps patients recognize warning signs and obtain timely assessment.

  Building an effective treatment routine

  Long-term outcomes depend on integrating pharmacology with education and follow-up. Clinicians can use a structured review at each visit to confirm the indication, assess technique, identify adverse effects, and determine whether the current device remains practical.

  Key prescribing and follow-up priorities include:

  • Confirm the COPD diagnosis and document symptom burden, exacerbation history, and relevant comorbidities.
  • Select a LAMA or LAMA/LABA device that matches inspiratory ability, dexterity, vision, cognition, and dosing preference.
  • Demonstrate the inhaler, ask the patient to repeat the steps, and correct errors without judgment.
  • Review adherence, rescue medication use, smoking exposure, vaccination status, and participation in pulmonary rehabilitation.
  • Reassess after treatment changes and escalate, simplify, or switch therapy according to clinical response.

  Anticholinergic therapy works best as part of a personalized respiratory plan rather than as an isolated prescription. Regular monitoring helps distinguish inadequate drug response from poor technique, ongoing irritant exposure, untreated anxiety, deconditioning, or another cause of breathlessness.

  Explore the APSR 2022 respiratory medicine resources and congress perspectives to deepen understanding of COPD pharmacotherapy, inhaler practice, and multidisciplinary approaches to patient care.

  Richard Russell Nuffield Department of Clinical Medicine, University of Oxford (United Kingdom)
• Mona Bafadhel King’s College London (United Kingdom)
  David Jackson Guy’s and St Thomas’ Hospital, King’s College London (United Kingdom)
• James Chalmers University of Dundee (United Kingdom)
  David Price University of Aberdeen (United Kingdom)